Background-Among the prostanoids, thromboxane (TX) A 2 is a potent stimulator of platelets, whereas prostaglandin (PG) I 2 inhibits their activation. The roles of PGE 2 in the regulation of platelet function have not been established, however, and the contribution of PGE 2 in hemostasis and thromboembolism is poorly understood. The present study was intended to clarify these roles of PGE 2 by using mice lacking the PGE 2 receptor subtype 3 (EP 3 Ϫ/Ϫ mice). 
A mong the prostanoids, thromboxane (TX) A 2 is a potent stimulator of platelets, whereas prostaglandin (PG) I 2 inhibits their activation. 1, 2 The role of PGE 2 in the regulation of platelet function, however, has not been established. In the circulatory system, PGE 2 is produced from several lines of cells. Activated platelets produce significant amounts of PGE 2 , 3,4 which increases 20-fold in the presence of a TXA 2 synthase inhibitor. 5 Macrophages are another source of PGE 2 , especially in an inflammatory situation. For example, although resident macrophages containing only cyclooxygenase 1 produce small amounts of PGE 2 , induction of cyclooxygenase 2 with lipopolysaccharide results in the preferential production of PGE 2 . 6 Platelets play a critical role not only in hemostasis but also in many pathological conditions, such as cerebral thrombosis, ischemic heart disease, and atherosclerosis, [7] [8] [9] in which they exert their actions by aggregating themselves and releasing bioactive substances. 9 -11 Because of these roles of platelets, PGE 2 produced in the circulatory system may have a great influence on hemostasis and many pathological conditions through the control of platelet function.
The actions of PGE 2 are mediated through rhodopsin-type cell surface receptors. 12 There are 4 subtypes of the PGE 2 receptor: EP 1 , EP 2 , EP 3 , and EP 4 . 12 Signaling of EP 1 13 PGE 2 has been reported to have a biphasic effect on platelet response, potentiating their aggregation at low concentrations and inhibiting it at higher concentrations. 14 It has been suggested that PGE 2 acts on a specific EP receptor to potentiate aggregation and that its inhibitory actions are mediated by the PGI 2 receptor (ie, IP). 15, 16 In fact, a specific binding site for [
3 H]PGE 2 has been demonstrated on human platelets, 17 and activation of this receptor has been suggested to lead to inhibition of adenylate cyclase through G i . 18 Matthews and Jones 19 compared the potentiating effects of various PGE analogues on aggregatory response and their effects on [cAMP] i in human platelets and suggested that the relevant receptor is "EP 3 -like" and mediates the potentiating effect of PGE 2 by inhibiting adenylate cyclase. The action of PGE 2 on platelets has been controversial, however, and its role in the regulation of platelet function has been largely unknown. This is because there have been no known agonists or antagonists strictly specific to each of the 4 subtypes of EP, which has prevented characterization of the receptors participating in the regulation of platelet function.
To explore the physiological and pathophysiological roles of PGE 2 , we generated mice lacking EP 3 (EP 3 Ϫ/Ϫ mice). 20 Moreover, AE-248, 21 a recently developed compound, shows higher selectivity to EP 3 compared with those of known EP 3 agonists such as sulprostone and M&B-28767. 22 In this report, we characterized the EP participating in the potentiating action of PGE 2 on platelet aggregation and clarified the roles of PGE 2 in vivo by using EP 3 Ϫ/Ϫ mice and AE-248.
Methods

Animals and Reagents
The generation and maintenance of EP 3 Ϫ/Ϫ mice have been reported previously. 20 All studies were performed on 8-to 12-week-old male and female mice except for the experiments involving arachidonic acid-and collagen/epinephrine-induced thromboembolism, in which only male mice were used. All experiments in this study were approved by the Asahikawa Medical College Committee on Animal Research. ADP, epinephrine, and PGE 2 were purchased from Sigma Chemical Co, and U46619 was from Cayman Chemical. Collagen reagent was purchased from Hormon Chemie. AE-248 was a gift from ONO Pharmaceuticals, Osaka, Japan.
Platelet Aggregation
Blood was taken by cardiac puncture from ether-anesthetized mice with a syringe containing 50 L of 3.8% trisodium citrate and was diluted with an equal volume of a buffer: 20 mmol/L HEPES, 140 mmol/L NaCl, 5 mmol/L MgCl 2 , and 5 mmol/L KCl (pH 7.4). The final concentration of trisodium citrate was adjusted to 0.38%. Platelet-rich plasma (PRP) was prepared by centrifugation at 800 rpm for 5 minutes. Platelet-poor plasma was obtained by further centrifugation at 3000 rpm for 10 minutes. The number of platelets in the PRP was adjusted to 3ϫ10 5 platelets/L. Platelet aggregation was measured with an aggregometer (PAT-4A, Nihon Koden). 23 U46619, a representative agonist for the TXA 2 receptor (TP), was used to activate the receptor. U46619 is not as potent a stimulator of murine platelets as it is of human platelets, however, inducing full aggregation of murine platelets at concentrations Ͼ20 mol/L.
Reverse Transcription-Polymerase Chain Reaction
PRP was carefully prepared to avoid contamination with leukocytes. After the addition of EDTA (7.7 mmol/L), PRP was centrifuged at 2000 rpm for 10 minutes. The platelet pellet was washed once and suspended in PBS. The purity of platelets estimated by hemocytometry was Ͼ99.9%. Total RNA was isolated from the platelets with Isogen (Nippon Gene). Total RNA (2 g) was reverse-transcribed (RT) with Moloney murine leukemia virus reverse transcriptase (Toyobo) and oligo-dT primers (Gibco-BRL). The resulting cDNA was amplified by 35 polymerase chain reaction (PCR) cycles with an annealing temperature of 60°C with primer sets specific for each prostanoid receptor. To quantify expression levels of the mRNAs for the EPs, we adopted competitive RT-PCR methods that included a competitive DNA construction kit (Takara). Primer sequences used were as follows: (1) for EP 1 , 5Ј primer 5Ј-CGCAGG-GTTCACGCACACGA-3Ј, 3Ј primer 5Ј-CACTGTGCCGGGAA-CTACGC-3Ј; (2) for EP 2 , 5Ј primer 5Ј-AG-GACTTCGATGGCAG-AGAGAC-3Ј, 3Ј primer 5Ј-CAGCCCCT-TACACTTCTCCAATG-3Ј; (3) for EP 3 , 5Ј primer 5Ј-GGTAT-GCCAGCCACAATGAAGAC-3Ј, 3Ј primer 5Ј-CAAGATCTGGT-TCAGCGAAGCC-3Ј; (4) for EP 4 , 5Ј primer 5Ј-TTCCGCTCGTGG-TGCGAGTGTTC-3Ј, 3Ј primer 5Ј-GAGGTGGTGTCTGCTT-GGGTCAG-3Ј; (5) for FP, 5Ј primer 5Ј-GCTCTTGGTGTTT-CCTTCTCGTC-3Ј, 3Ј primer 5Ј-GTGACTCA-GAAATAGCAG-CAACC-3Ј; (6) for TP, 5Ј primer 5Ј-CTCGG-GACACAGCG-CGGTGAC-3Ј, 3Ј primer 5Ј-GATATAGACC-CAGGGGTCCAAG-3Ј; (7) for IP, 5Ј primer 5Ј-GGCACGAGA-GGATGAAGTTT-3Ј, 3Ј primer 5Ј-GTCAGAGGCACAGCAG-TCAATGG-3Ј; and (8) for DP, 5Ј primer 5Ј-GCTTTCTGTGCG-CTCCCCTTTG-3Ј, 3Ј primer 5Ј-CATCCGGAATACTGAAG-TCCTG-3Ј.
Calcium Measurements
Washed platelets prepared as described previously 23 
Bleeding Time
Bleeding times were assessed according to a previously reported method. 25 In brief, mice were placed in a holder, and their tails were transected 1 cm proximal from the tip. The remaining tail was immersed immediately into PBS maintained at 37°C, and the time during which visible bleeding was observed was measured.
Thromboembolism Induced by Arachidonic Acid and Collagen/Epinephrine
Acute thromboembolism was assessed with an established model. 26 Into conscious male mice, 62.5 mg/kg body wt of arachidonic acid was injected into the tail vein. Survival was evaluated 1 hour after injection, because the mice alive at 1 hour usually recovered from this challenge. For histological examination, mice were humanely killed 3 minutes after injection, and the lungs were excised. Tissue preparations were stained with hematoxylin and eosin. We also assessed acute thromboembolism in another model. 27 Into conscious male mice, 2 mg/kg of collagen and 120 mg/kg of epinephrine dissolved in a buffer included in the collagen reagent were injected into the tail vein. The amount of collagen and epinephrine used was determined as that which induced mortality of 80% to 90% in wild-type mice.
Results
Expression of mRNAs of Prostanoid Receptors in Murine Platelets
We first examined whether mRNAs of the EPs were expressed in murine platelets by the RT-PCR method ( Figure  1 U46619-induced platelet aggregations were similar between wild-type and EP 3 Ϫ/Ϫ mice (Figure 2A ), indicating that there was no difference in the sensitivity of platelets to U46619 between these mice. In wild-type mice, PGE 2 potentiated U46619-induced platelet aggregation concentration-dependently, with an EC 50 value of 10 nmol/L ( Figure 2B ). Similar potentiating effects of PGE 2 were observed on ADP-induced aggregation (data not shown). PGE 2 at concentrations of 30 mol/L or higher showed inhibitory effects on aggregation (data not shown), probably because of the cross-action of PGE 2 on IP. 15 
Ϫ/Ϫ mice, the potentiating action of PGE 2 disappeared completely, and an inhibitory action, probably via IP, was disclosed ( Figure 2B ). In wild-type mice, AE-248 also potentiated the U46619-induced aggregation (Figure 3A) . In EP 3 Ϫ/Ϫ mice, however, AE-248 lost this action completely ( Figure 3B ). Although AE-248 itself could not induce platelet aggregation, it did induce a shape change at concentrations of Ն30 mol/L (data not shown). These results clearly show that EP 3 mediates the potentiating effect of PGE 2 on platelet aggregation. It is notable that U46619 at concentrations of Յ2 mol/L could induce full aggregation in the presence of PGE 2 or AE-248, because U46619 alone at these concentrations could induce only small, reversible aggregations ( Figures 2B and 3A) .
Signaling of the Potentiating Effect of PGE 2 Mediated by EP 3
In wild-type mice, both PGE 2 
Increased Bleeding Tendency and Decreased Susceptibility to Thromboembolism in EP 3 ؊/؊ Mice
The bleeding times were 141Ϯ17 and 353Ϯ46 seconds in wild-type and in EP 3 Ϫ/Ϫ mice, respectively ( Figure 5A ). This Although primers used for amplification of EP 1 , DP, and FP worked well with cDNAs prepared from kidney, ileum, and aorta, respectively, these primers failed to amplify respective band with cDNAs from platelets. result clearly showed that endogenous PGE 2 plays an important role in hemostasis via EP 3 . Because it is generally accepted that TXA 2 plays a major role in hemostasis, this result is surprising and may suggest that the concentration of TXA 2 generated in this condition could not fully activate the platelets by itself but required the potentiating action of PGE 2 . To validate this assumption, we next examined the acute thromboembolism induced by arachidonic acid, in which TXA 2 is known to play a main role. As shown in Figure 4B , 8 of 10 wild-type mice died within 10 minutes of injection of arachidonic acid. In contrast, 8 of 9 EP 3 Ϫ/Ϫ mice survived. Histological examination showed marked thrombus formation in the arterioles of the lung from wild-type mice. Alveolar hemorrhage was also observed in broad areas, which frequently accompanied massive pulmonary thrombosis (Figure 5C and 5D ). In contrast, little evidence of such thrombus formation or alveolar hemorrhage was found in the lungs from EP 3 Ϫ/Ϫ mice ( Figure 5E and 5F). We further examined the acute thromboembolism induced by collagen and epinephrine, in which the mediator of thromboembolism is independent of prostanoid production. There was no difference in mortality between the wild-type and the EP 3 Ϫ/Ϫ mice: 10 of 12 and 9 of 12 mice, respectively, died within 15 minutes of injection. These findings suggest an important pathological role for PGE 2 in acute thromboembolism, again via EP 3 , and suggest that this role is dependent on the production of PGE 2 in relevant pathological conditions.
Discussion
The expression of mRNAs of EP 3 and EP 4 has recently been reported in human platelets, 28 but precise expression levels of these receptors are unclear. We found significant expression of EP 3 mRNA, whereas those for EP 2 and EP 4 were much lower. There is a limitation, however, to the use of RT-PCR for determination of expression level of mRNA in platelets, because of possible contamination of mRNAs from leukocytes. This limitation, however, could be overcome by examining the platelet function in mice lacking EP 3 , and the role of the EP 3 expressed in platelets was verified functionally in this study.
To assess the in vitro and in vivo roles of PGE 2 in the regulation of platelet function, we used mice lacking EP 3 and a specific EP 3 agonist, AE-248. We first examined the effects of PGE 2 on platelet aggregation and demonstrated for the first time that EP 3 mediates the potentiating effect of PGE 2 on platelet aggregation. Although extremely high concentrations of PGE 2 inhibited the aggregations induced by U46619 and ADP, this inhibitory effect may be derived from cross-action of PGE 2 on IP as suggested. 15, 16 We next examined the signaling of PGE 2 in platelets. The potentiating effect of PGE 2 on platelet aggregation has been Although the in vitro effects of PGE 2 on platelet aggregation have been reported, the roles of PGE 2 in the regulation of platelet function in vivo have not been known. To clarify these roles of PGE 2 , we tried 2 models in which platelet activation is thought to contribute critically: bleeding time and acute thromboembolism. Surprisingly, the bleeding time was significantly increased in EP 3 Ϫ/Ϫ mice compared with that in wild-type mice. Moreover, EP 3 Ϫ/Ϫ mice displayed a strong resistance to arachidonic acid-induced thromboembolism. These results show that PGE 2 via EP 3 plays a key role in hemostasis and acute thromboembolism. TXA 2 , however, has been thought to be a major player in these experimental models 29 and in vivo. In fact, mice lacking TP have recently been reported to show increased bleeding time and decreased resistance to thromboembolism, 30 and we reported that naturally occurring mutations of the TP gene cause an abnormal bleeding tendency. 31 Taken together, these results may suggest a novel mechanism involved in hemostasis and acute thromboembolism; that is, although both TXA 2 and PGE 2 are produced at the site of hemostasis or thrombus formation, the concentration of TXA 2 achieved is too low to fully activate the platelets by itself, requiring the potentiating action of PGE 2 .
The roles of PGE 2 demonstrated in this study probably could not be directly applied to humans, because there may be some differences in the expression of the prostanoid receptors between human and mouse platelets. EP 3 , however, might play a role in mediating the action of PGE 2 in physiological and pathological conditions. Thus, the roles established here for PGE 2 may lead to the development of novel drugs, which would act specifically on EP 3 and could modulate platelet function in various pathological conditions.
